Ascentage Pharma's EBIT loss and liabilities compared to cas...

Moomoo AI Dec 20, 2023 09:06

Ascentage Pharma's EBIT loss and liabilities compared to cash and near-term receivables raise debt usage concerns. The company's stock position appears risky after burning through CN¥814m of cash in a year.

Is Ascentage Pharma Group International (HKG:6855) A Risky Investment?

Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates. Read more

Translate

Report

9470 Views

Comment

Moomoo AI

Moomoo AI Official Account

Your AI assistant for discovering investment opportunities.

4952

Followers

Following

11K

Visitors